Ivermectin Solution Bioequivalence Study - With Food (Repeat)

You may not qualify if:

• Illness within 14 days before the start of the study
• Hospitalisation within 3 months before the start of the study (at the discretion of the Investigator)
• Participation in a clinical trial in which blood was taken within 16 weeks before the start of the study
• Participation in a clinical trial in which a volume of blood exceeding 500 ml was taken within 12 months before the start of the study
• Donation of blood or plasma within 90 days before the start of the study
• Any indication of current or previous abuse of alcohol, solvents or drugs
• Treatment with a full or regular course of medication during the 28 days before the start of the study or with any proscribed medication during the 14 days before the start of the study
• Use of alcohol on study days or within 24 hours prior to commencement of each study period
• Intake of grapefruit products within 7 days before the start of the study
• Intake of methylxanthine-containing beverages within 24 hours prior to each study period
• Intake of quantities of methylxanthine or alcohol-containing beverages which, in the opinion of the Investigator are abnormal (habitually taking more than 5 cups or glasses of tea, coffee, cola, chocolate etc. per day or habitually taking more than 20 g alcohol/day)
• Patient is pregnant, or lactating/breastfeeding (female volunteers only) Diet, which in the opinion of the Investigator, deviates from a normal diet (e.g. vegans)
• Patients who have resided in areas of Africa known to be endemic for Onchocerca volvulus (onchocerciasis or river blindness), wuchereria bancrofti (lymphatic filariasis), Loa loa or other microfilaremic disease
• Patients with a known or suspected intestinal helminth infection, such as Strongyloides stercoralis or other intestinal helminth
• Patients with a known hypersensitivity to any component of the Ivermectin product